Efficacy and Safety of Sacubitril-valsartan Combined with Tolvaptan in Patients with Heart Failure:A Meta-analysis
Objective To systematically evaluate the efficacy and safety of sacubitril-valsartan combined with tolvaptan in patients with heart failure.Methods The Cochrane Library EMbase,PubMed,CNKI,Wangfang,VIP,CBM databases were performed to identify the clinical studies of sacubitril-valsartan combined with tolvaptan in patients with heart failure from library building to October 23,2023.Meta-analysis was performed using Revman 5.3.Results A total of 115 articles about sacubitril-valsartan combined with tolvaptan in patients with heart failure were retrieved,and 23 articles were included,totaling 2 560 patients with heart failure.Meta-analysis results showed that the total clinical effective rate[OR=4.39,95％CI(3.25-5.92),P＜0.000 01],LVEF[MD=4.92,95％CI(3.99-5.86),P＜0.000 01],LVESD[MD=-4.31,95％CI(-5.26--3.36),P＜0.000 01],LVEDD[MD=-3.62,95％CI(-5.12--2.12),P＜0.000 01]and other indicators in the sacubitril-valsartan combined with tolvaptan group were significantly higher than those in the control group.Regarding safety,the incidence of adverse effects in the combination group was close to the control group.Conclusion Sacubitril-valsartan combined with tolvaptan can effectively improve the cardiac and renal function in patients with heart failure,especially hyponatremia,which is good safety with no serious adverse effects.
万方数据
维普
